



Tanvex BioPharma Elects Henry Chen as Chairman

December 29, 2023

Tanvex BioPharma, Inc., elected Henry Chen to take over as chairman during a temporary board meeting convened on December 29. Chen has a background in law and finance and is well acquainted with Tanvex's operations. His return as chairman will have a synergistic effect on Tanvex's future development.

Chen holds Bachelor's and Master's degrees from Harvard University and a Juris Doctorate from Harvard Law School. Chen previously served as a director on Tanvex's board and as company Chief Financial Officer before becoming Chief Executive Officer in 2020. In 2021, Chen took over as Chairman from company founder Dr. Allen Chao, a role he later passed to Dr. Yun Yen. Chen is keenly familiar with the company's development and operations and will lead the Tanvex management team in deepening the company's vertical and horizontal resource integration, leveraging operational advantages, and creating the most value for its shareholders, employees, and customers.

As Tanvex's biosimilar drugs enter commercialization, the company is transitioning from a research and development company toward the critical stages of commercialization. Coupled with its successful entry into the CDMO business and the development of new drugs, Tanvex is well-prepared and ready for the future.

About Tanvex

Tanvex BioPharma, Inc. (TWSE: 6541) is a biopharmaceutical company focused on the biosimilar market. The Company is vertically integrated with end-to-end in-house development, manufacturing and commercialization capabilities. Tanvex BioPharma, Inc. is registered in Cayman Islands and has operations and facilities in Irvine, CA, San Diego, CA, and Taipei, Taiwan. Tanvex is publicly traded on the Taiwan Stock Exchange.